These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29027130)

  • 21. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regulatory aspects of biosimilars. Myths and facts].
    Schneider CK; Weise M
    Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
    Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
    BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of animal studies to evaluate the similarity of biosimilars to reference products.
    van Meer PJ; Ebbers HC; Kooijman M; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    Drug Discov Today; 2015 Apr; 20(4):483-90. PubMed ID: 25463036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody biosimilars: fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France.
    Guillon-Munos A; Daguet A; Watier H
    MAbs; 2014; 6(4):805-9. PubMed ID: 24714167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Regulatory Perspective on Biosimilar Medicines.
    Cordeiro MA; Vitorino C; Sinogas C; Sousa JJ
    Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study.
    Rahalkar H; Sheppard A; Lopez-Morales CA; Lobo L; Salek S
    Pharmaceut Med; 2021 Jul; 35(4):235-251. PubMed ID: 34292558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory landscape for cell therapy--EU view.
    McBlane JW
    Biologicals; 2015 Sep; 43(5):433-6. PubMed ID: 25997566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Path Towards a Tailored Clinical Biosimilar Development.
    Schiestl M; Ranganna G; Watson K; Jung B; Roth K; Capsius B; Trieb M; Bias P; Maréchal-Jamil J
    BioDrugs; 2020 Jun; 34(3):297-306. PubMed ID: 32266678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biosimilars : Current state of the build up to series production].
    Aringer M; Dörner T
    Z Rheumatol; 2013 Nov; 72(9):873-7. PubMed ID: 23934050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.